Lupin Limited has named Brian Savage as Senior Management Personnel, appointing him as President and Chief Legal Officer, effective October 22, 2026. In this role, he will oversee Lupin’s global legal, compliance, and intellectual property functions, signaling a sharpened focus on governance as the Indian drugmaker extends its international reach.
Savage arrives with a track record of legal leadership in the global pharmaceutical sector. He previously served as Executive Vice President and Interim Global Chief Legal Officer at Teva Pharmaceuticals, with prior experience at Dechert LLP. He holds a Juris Doctor degree from Yale Law School and a Bachelor of Arts from the University of Pennsylvania, credentials that underscore a blend of high-stakes legal acumen and strategic business partnering.
At Lupin, he will help steer the company’s regulatory posture and IP strategy, ensuring rigorous compliance and robust risk management as the company translates research into commercial medicines across markets. The appointment strengthens Lupin’s executive leadership for navigating a complex, fast-moving global pharmaceutical landscape and signals the company’s commitment to integrating legal and business strategy at the highest levels.
This leadership move reflects Lupin’s ongoing emphasis on fortifying governance and strategic execution at the top tier, as it continues to chart its path in a dynamic global healthcare environment.